Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Immuneering CorporationNASDAQ: IMRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $13.46M (cash outflow) fell 10.5% year over year, ahead of the -11.9% change in trailing-twelve-month net income. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$53.31M (-4.8%) for the fiscal year ending Dec 2026, a step up from the -8.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$13.46M+16.2% QoQ
- Last fiscal yearDec 2025
- -$56.02M-8.2% YoY
- LTMMar 2026
- -$54.44M-11.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.5% | +20.4% | +30.9 pp |
| 1 year | -8.2% | -4.8% | +3.4 pp |
| 3-year CAGR | +3.5% | +5.5% | +2.0 pp |
| 5-year CAGR | -50.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (56.02M) USD
- Year-over-year change
- +8.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (56.02M) | +8.2% |
| FY2024 | 2024-12-31 | (61.04M) | -14.1% |
| FY2023 | 2023-12-31 | (53.47M) | -5.9% |
| FY2022 | 2022-12-31 | (50.51M) | -50.6% |
| FY2021 | 2021-12-31 | (33.54M) | — |
Net Income vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 net income of $54.44M is the 10th largest of the 11 companies compared; the peer median is $78.05M.
- Its year-over-year change of -11.9% is the 5th highest of 11, against a peer median of -15.5%.
- Over three fiscal years its annual growth of +3.5% compares with a peer median of -9.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $166.12M | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $83.01M | -21.5% | -9.9% | 36891.1% | |
| LTM Mar 2026 | $81.74M | -14.2% | -13.0% | 589.8% | |
| LTM Mar 2026 | $78.67M | +15.4% | — | 173.5% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $61.98M | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $57.09M | -16.9% | +0.6% | — | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| LTM Mar 2026 | $6.38M | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding IMRX) | $78.05M | -15.5% | -9.9% | 428.3% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Depreciation & Amortization | 159.07K | 796.79K | 352.08K | 385.07K | 698.89K |
| Deferred Income Tax | (307.49K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.8M | 0 | 5.73M | 6.5M | 0 |
| Change in Working Capital | 900.42K | 1.72M | (974.64K) | (925.38K) | 3.82M |
| Accounts Receivables | 279.71K | 233.62K | 12.42K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (130.4K) | 1.76M | (1.11M) | (112.14K) | (400.8K) |
| Other Working Capital | 751.1K | (276.56K) | 119.84K | (813.24K) | 4.22M |
| Other Non-Cash Items | 130.24K | 3.9M | (601.59K) | 75.98K | 6.16M |
| Operating Cash Flow | (30.85M) | (44.1M) | (48.97M) | (55M) | (45.34M) |
| Capital Expenditures | (60.79K) | (742.49K) | (342.75K) | (84.88K) | (142.23K) |
| Acquisitions (Net) | 70.35K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (75.63M) | (50.1M) | (44.66M) | (5.41M) | (88.6M) |
| Sales of Investments | 75.62M | 92.68M | 52.3M | 31.93M | 0 |
| Other Investing Activities | (75.62M) | 0 | 0 | 0 | 247 |
| Investing Cash Flow | (75.62M) | 41.83M | 7.3M | 26.43M | (88.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 120.32M | 19K | 28.2M | 4.24M | 226.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (842.76K) | 0 | 241.07K | 1.07M | (147) |
| Financing Cash Flow | 144.26M | 19K | 28.44M | 5.3M | 226.58M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.8M | (2.25M) | (13.23M) | (23.26M) | 92.5M |
| Free Cash Flow | (30.91M) | (44.84M) | (49.31M) | (55.08M) | (45.49M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.